



IJPPR

INTERNATIONAL JOURNAL OF PHARMACY & PHARMACEUTICAL RESEARCH
An official Publication of Human Journals

ISSN 2349-7203



Human Journals

Review Article

May 2022 Vol.:24, Issue:2

© All rights are reserved by Kavade K.A. et al.

Omicron SARS-CoV-2 Variant: A Review



IJPPR
INTERNATIONAL JOURNAL OF PHARMACY & PHARMACEUTICAL RESEARCH
An official Publication of Human Journals



ISSN 2349-7203

Kavade K.A. ^{1*}, Kanavade R.R. ², Sahani K.R. ³, Patil R.N. ⁴

Ashvin College of Pharmacy, Manchi Hill, Tal- Sangamner, Dist- Ahmednagar, Pin- 413714. India.

Submitted: 21 April 2022
Accepted: 27 April 2022
Published: 30 May 2022

Keywords: Variant, Unpredictable, Evaluate Diagnosis, Spreadability, Covid -19, Delta Variant

ABSTRACT

The Omicron was first collected in November 2021 in the Gauteng province of South Africa. The current situation is that world facing unpredictable problems with a different variant of covid-19. The call suggests that omicron has the potential to cause substantial Surges in case of hospital admission and death. The free introduction may be required to prevent hospital admission from exceeding the levels. The WHO Designated the variant B. 1. 1.529 a variant of concern VOC on 26 November 2021, based on advice from the technical advisory group on virus evolution. The current Limited evidence of omicron appears to have a growth advantage over the delta. The cases of human infection with this variant have been identified in 63 countries across all Six Who regions. The scientist is working on it so there is a need for you always threatens raised with a new variant. The present review includes history, protein structure, diagnosis, the potency of a vaccine, and the spreadability of vaccines.



www.ijppr.humanjournals.com

INTRODUCTION:-

On 24th November 2021 Omicron variant (B.1.1.529) is a variant of SARS-CoV-2 (the virus that causes COVID-19) that was first reported to the World Health Organization (WHO) from South Africa. ^(1,2) Omicron multiplies around 70 times faster than the Delta variant in the bronchi (lung airways) but evidence suggests it is less severe than previous strains, especially compared to the Delta variant. ^(3,4) Lungs tissues are less penetrated by omicron. ⁽⁵⁾ Omicron infections are 91 percent less fatal than the delta variant. ⁽⁶⁾ However, the estimated difference in intrinsic hospitalization risk largely decreases to 0-30 percent when reinfections are discounted.⁽⁷⁾



Omicron virus ⁽⁸⁾


The variant has an unusually large number of mutations, several of which are novel and several of which affect the spike protein used for a most vaccine targeting at the time of its discovery. This level of variation has led to concerns regarding transmissibility, immune system evasion, and vaccine resistance. The variant was quickly designated as being "of concern", and travel restrictions were introduced by several countries to limit or slow its international spread. The variant has an unusually large number of mutations, several of which are novel and several of which affect the spike protein used for most vaccine targeting at the time of its discovery • This level of variation has led to concerns regarding transmissibility, immune system evasion, and vaccine resistance. In Several countries, the variant was quickly designated as being "of concern". Its travel restrictions were introduced to limit or slow its international till. ⁽⁹⁾

History:-

Classification:-

The TAG-VE was convened on 26 November 2021 to assess the SARS-CoV-2 variant: B.1.1.529. An independent group of experts which is the Technical Advisory Group on SARS-CoV-2 Virus Evolution (TAG-VE) is a that periodically monitors and evaluates the evolution of SARS-CoV-2 and assesses if specific mutations and combinations of mutations alter the behavior of the virus. ⁽¹⁰⁾

In recent weeks, infections have increased steeply, coinciding with the detection of the B.1.1.529 variant. The first known confirmed B.1.1.529 infection was from a specimen collected on 9 November 2021. On 24th November 2021, the B.1.1.529 variant was first reported to WHO from South Africa on the epidemiological situation in South Africa has been characterized by three distinct peaks in reported cases, the latest of which was predominantly the Delta variant. ⁽¹¹⁾



Distribution of omicron virus over the world ⁽¹²⁾

As compared to other VOC's Preliminary evidence suggests an increased risk of re-infection of variant. The number of cases of this variant appears to be increasing in almost all provinces in South Africa. To detect virus Current SARS-CoV-2 PCR diagnostics continue

Several labs have indicated that for one widely used PCR test, one of the three target genes is not detected (called S gene dropout or S gene target failure) and this test can therefore be used as a marker for this variant, pending sequencing confirmation. ⁽¹¹⁾

Difference between omicron and covid-19

The Omicron variant has more mutable capability than Delta; it doesn't mean it is more dangerous than other variants. So far, no new symptoms were reported due to the omicron variant; in the future, it may spread faster than other variants because of its mutations. The expected spreading with mutations of the two variants, till now one death case reported due to omicron variant in the UK [7] the virus that causes COVID-19, SARS-CoV-2, has the greatest mutations of any kind. We still haven't figured out how those genetic changes work. However, they remain for a reason: they aid in the success of a variety.




Figure 2. Different spike proteins between delta and omicron variants of SARS-COVID-19-2

1. Delta Variant


According to Suresh V. Kuchipudi of Penn State University, who researches viral evolution, two are in a molecular hook called the "receptor-binding domain," which helps it attach to cells more tightly. A protrusion on the virus's surface that aids in the virus's attachment to human tissues, nine variations in the spike protein was observed.

2. Omicron Variant

Within the next few weeks, we will know better information about the omicron variant growth rates in other geographies. It's a mutation monster, with at least 32 mutations in the spike protein and ten in the receptor-binding domain. ⁽⁸⁾ In general, two or three people were infected with the first SARS-CoV-2 virus. Delta changed everything by infecting about six people. Delta has a four-day incubation period, which is lower than the six-day incubation period of the original virus, making people contagious sooner. The omicron's transmission rate and incubation period are unknown. Within the next few weeks, we will know better information about the omicron variant growth rates in other geographies.

Symptoms:-

The WHO and the global scientific community have cautioned against concluding after two South African health experts said that omicron symptoms had so far been mild flu-like with dry cough, fever, night sweat, and body pains. ⁽¹²⁾



- The most common symptoms of omicron are:- Cough, loss of taste, smell, taste, and fever.
- Less common symptoms of omicron:- Sore throat headache, aches, pain, diarrhea, a rash on the skin, decoloration of fingers or toes red or irritated eyes.

- Serious symptoms of omicron:- Difficulty breathing or shortness of breath, loss of speech or mobility or confusion or chest pain.
- Unusual symptoms of omicron:- Loose motions and abdominal cramps, Richard has Hospital the unusual symptoms in this were loose motion and abdominal cramps. ⁽¹⁵⁾
- Impact on immunity (following infection or vaccination):- Current evidence consistently shows a reduction in neutralizing titers against Omicron in individuals who have received a primary vaccination series or in those who have had prior SARS-CoV-2 infection. In addition, an increased risk of re-infection has been reported in South Africa, the United Kingdom, Denmark, and Israel. There is a growing body of evidence on vaccine effectiveness (VE) for Omicron, with data available from 15 observational studies from five countries (the United Kingdom, Denmark, Canada, South Africa, and the United States of America), evaluating four vaccines (mRNA vaccines, Ad26.COV2.S, and AstraZeneca-Vaxzevria). Available preliminary data should be interpreted with caution because the designs may be subject to selection bias and the results are based on relatively small numbers. Early data suggest that the effectiveness of studied vaccines is significantly lower against Omicron infection and symptomatic disease compared to Delta, with homologous and heterologous booster doses increasing vaccine effectiveness. Despite this, follow-up time after booster doses for most studies is short, and there is evidence of waning of VE in months following booster doses. VE estimates against severe outcomes, usually defined as hospitalization, are lower for Omicron than Delta, but mostly remain greater than 50% after the primary series and improve with a booster dose to above 80%. More data are needed to assess these preliminary findings across studies, vaccine platforms, and dosing regimens. There is no effective data for several vaccines, particularly the inactivated vaccines. ⁽¹⁶⁾
- Impact on host tropism, virus fitness, and pathogenicity:- Preliminary evidence suggests a potential shift in the tropism of the Omicron variant towards the upper respiratory tract, as compared to Delta and the wild type (WT) virus that has a tropism for the lower respiratory tract. There is also evidence of less severe pathogenicity in the Syrian hamster (*M. auratus*) model, but this needs to be confirmed by peer-reviewed evidence and larger studies. ⁽¹⁷⁾
- Impact on therapeutics and treatments:- Therapeutic interventions for the management of patients with severe or critical Omicron-associated COVID-19 that target host responses (such as corticosteroids, and interleukin-6 receptor blockers) are expected to remain effective.

However, preliminary data from non-peer-reviewed publications suggest that some of the monoclonal antibodies developed against SARS-CoV-2 may have impaired neutralization against Omicron. Monoclonal antibodies will need to be tested individually for their antigen binding and virus neutralization, and these studies should be prioritized. Preliminary in vitro data suggest that antivirals retain activity against Omicron. ⁽¹⁸⁾

Transmission:-

- Omicron has been found to have a significant growth advantage, higher secondary attack rates, and a higher observed reproduction number compared to Delta. ⁽¹⁹⁾
- An analysis of GISAID data following a previously published methodological approach (shows a growth rate advantage of Omicron over Delta in all countries with sufficient sequence data, translating to a pooled mean transmission advantage (i.e. relative difference in effective reproduction numbers) of 189% (95% Confidence Interval: 162% - 217%) across epidemiological contexts under the assumption of an unchanged generation time. However, early evidence for a reduced generation time of Omicron ⁽²⁰⁾ suggests the transmission advantage may be lower; for a 20% shorter generation time. ^(21, 22, 23)
- Household transmission studies further corroborate the transmission advantage of Omicron. For example, household secondary attack rates for Omicron consistently show higher values compared to Delta. ^(24, 25)
- The transmission advantage of Omicron appears to be largely driven by immune evasion, but also potential increased intrinsic transmission fitness. ⁽²⁶⁾
- While there is significant evidence of immune evasion against transmission from infection and vaccine-derived immunity (see later sections), more data are needed to better understand the relative contribution of intrinsic increased transmission fitness and immune evasion in explaining transmission dynamics. ⁽²⁷⁾
- There is evidence that the Omicron variant infects human bronchus tissue faster and more efficiently than Delta and outcompetes Delta in competition experiments using cells derived from the human nose, but not in lung-derived cells. ⁽²⁸⁾
- This points to a predominance of viral replication in the upper respiratory tract that may confer, at least to some extent, a transmission advantage independent of immune evasion. Preliminary results from South Africa have suggested that if there is intrinsic higher

transmission fitness, it is likely modest, with some analyses suggesting that immune evasion levels of 25% to 50% could explain the observed growth advantage, even without an increase in intrinsic transmissibility. Another study from South Africa (non-peer-reviewed) estimates that Omicron is 36.5% (95% CI 20.9-60.1) more transmissible than Delta and that Omicron erodes 63.7% (95%CI 52.9-73.9) of the population immunity accumulated from prior infection and vaccination. Further studies are required to better understand the drivers of transmission, and declining incidence in various settings. ⁽²⁹⁾

- These factors include the intrinsic transmission fitness properties of the virus, degree of immune evasion, the level of vaccine-derived and post-infection immunity, levels of social mixing, and degree of application of public health and social measures. ⁽³⁰⁾

Prevention and control:-

Countries can and must prevent the spread of Omicron with proven health and social measures. Our focus must continue to be to protect the least protected and those at high risk,” said Dr. Poonam Khetrapal Singh, Regional Director, WHO South-East Asia Region. The overall threat posed by Omicron largely depends on three key questions – its transmissibility; how well the vaccines and prior SARS-CoV-2 infection protect against it, and how virulent the variant is as compared to other variants. We must continue to do it all. Protect yourself and protect each other. Get vaccinated, wear a mask, keep a distance, open windows, clean your hands, and cough and sneeze safely. Continue to take all precautions even after taking vaccine doses,” the Regional Director said. ⁽³¹⁾

CONCLUSION:-

Based on the available evidence including the recent publication mentioned above, who continue? The World Health Organisation (WHO) has called the recent surge in cases 'tip of the iceberg'. The outbreak of the new variant, the 'stealth' sub-variant of Omicron has many worried. All variants of COVID-19, including the Delta variant that is dominant worldwide, can cause severe disease or death, in particular for the most vulnerable people, and thus prevention is always key.

REFERENCES:-

- 1) a b c d e "Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern". World Health Organization. 26 November 2021. Archived from the original on 26 November 2021. Retrieved 26 November 2021.

- 2) a b Gowrisankar A, Priyanka TM, Banerjee S (10 January 2022). "Omicron: a mysterious variant of concern". *The European Physical Journal Plus*. 137 (1): 100. doi:10.1140/epjp/s13360-021-02321-y. ISSN 2190-5444. PMC 8743750. PMID 35036269.
- 3) Harvard Medical School (6 January 2022). "Coronavirus Resource Center - Harvard Health". Harvard Health Publishing. Archived from the original on 11 January 2022. Retrieved 7 January 2022. Lab studies, animal studies, and epidemiological data all indicate that Omicron may cause less severe disease than previous variants.
- 4) David Leonhardt (5 January 2022). "Omicron Is Milder". *The New York Times*. Archived from the original on 6 January 2022. Retrieved 7 January 2022. A few weeks ago, many experts and journalists were warning that the initial evidence from South Africa — suggesting that Omicron was milder than other variants — might turn out to be a mirage. It has turned out to be real.
- 5) a b "Lung tissue study sheds light on fast Omicron spread". CIDRAP. Archived from the original on 16 December 2021. Retrieved 25 December 2021.
- 6) Lewnard, Joseph A.; Hong, Vennis X.; Patel, Manish M.; Kahn, Rebecca; Lipsitch, Marc; Tartof, Sara Y. (11 January 2022). "Clinical outcomes among patients infected with Omicron (B.1.1.529) SARS-CoV-2 variant in southern California": 2022.01.11.22269045. doi:10.1101/2022.01.11.22269045. S2CID 245851556. Archived from the original on 16 January 2022. Retrieved 17 January 2022.
- 7) "Some reduction in hospitalisation for Omicron v Delta in England: early analysis". Imperial College London. Archived from the original on 22 January 2022. Retrieved 22 January 2022.
- 8) Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern". World Health Organization. 26 November 2021. Archived from the original on 26 November 2021. Retrieved 26 November 2021. • Parekh, Marcus; Platt, Poppie; Team, Global Health Security; Barnes, Joe (26 November 2021). "Coronavirus latest news: EU suspends all flights to southern Africa over omicron Covid variant fears". *The Telegraph*. ISSN 0307-1235. Archived from the original on 26 November 2021. Retrieved 26 November 2021. •
- 9) Google Image
- 10) WHO report news?
- 11) Report of WHO.
- 12) Google Image.
- 13) News article.
- 14) Google Image.
- 15) News article.
- 16) Enhancing response to Omicron SARS-CoV-2 variant:-Technical brief and priority actions for Member States World Health Organization: Headquarters, Geneva, Switzerland Update #6: 21 January 2022 (updated from previous version, dated 7 January 2022) .
- 17) Enhancing response to Omicron SARS-CoV-2 variant: Technical brief and priority actions for Member States World Health Organization: Headquarters, Geneva, Switzerland Update #6: 21 January 2022 (updated from previous version, dated 7 January 2022) .
- 18) Enhancing response to Omicron SARS-CoV-2variant: Technical brief and priority actions for Member States World Health Organization: Headquarters, Geneva, Switzerland Update#6:21 January 2022 (updated from previous version, dated 7 January 2022).
- 19) Campbell F, Archer B, Laurenson-Schafer H, Jinnai Y, Konings F, Batra N, et al. Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021. *Eurosurveillance* [Internet]. 2021 Jun 17 [cited 2022 Jan 21];26(24). Available from: [https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.24.2100509.\(20\)](https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.24.2100509.(20)) . UK Health Security Agency. Omicron daily overview: 31 December 2021 [Internet]. 2021 Dec [cited 2022 Jan 9]. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1044522/20211231_OS_Daily_Omicron_Overview.pdf.
- 20) 13. Kim D, Jo J, Lim J-S, Ryu S. Serial interval and basic reproduction number of SARS-CoV-2 Omicron variant in South Korea [Internet]. 2021 [cited 2022 Jan 9]. Available from: <https://www.medrxiv.org/content/10.1101/2021.12.25.21268301v1.full.pdf>



- 21) Abbott S, Sherratt K, Gerstung M, Funk S. Estimation of the test to test distribution as a proxy for generation interval distribution for the Omicron variant in England [Internet]. *Epidemiology*; 2022 Jan [cited 2022 Jan 21]. Available from: <http://medrxiv.org/lookup/doi/10.1101/2022.01.08.22268920>
- 22) Overton C, Ward T. Infectious Disease Modelling Team Omicron and Delta serial interval distributions from UK contact tracing data [Internet]. UK Health Security Agency; 2021 [cited 2022 Jan 21]. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1046481/S1480_UKHSOmicron_serial_intervals.pdf.
- 23) UK Health Security Agency. Technical briefing 33: SARS-CoV-2 variants of concern and variants under investigation in England [Internet]. 2021 [cited 2022 Jan 21]. Available from:- https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1043807/technical-briefing-33.pdf
- 24) Lyngse FP, Mortensen LH, Denwood MJ, Christiansen LE, Møller CH, Skov RL, et al. SARS-CoV-2 Omicron VOC Transmission in Danish Households [Internet]. *Infectious Diseases (except HIV/AIDS)*; 2021 Dec [cited 2022 Jan 5]. Available from: <http://medrxiv.org/lookup/doi/10.1101/2021.12.27.21268278>.
- 25) Pearson C, Silal S, Li M, Dushoff J, Bolker B, Abbott S, et al. Bounding the levels of transmissibility & immune evasion of the Omicron variant in South Africa [Internet]. 2021 Dec. Available from: https://www.Sacmc.epidemicexplorer.co.za/downloads/Pearson_etal_Omicron.pdf.
- 26) Chan MCW, Hui KP, Ho J, Cheung M, Ng K, Ching R, et al. SARS-CoV-2 Omicron variant replication in human respiratory tract ex vivo [Internet]. In Review; 2021 Dec [cited 2022 Jan 9]. Available from: <https://www.researchsquare.com/article/rs-1189219/v1>.
- 27) Brown J, Zhou J, Peacock T, Barclay W. The SARS-CoV-2 variant, Omicron, shows enhanced replication in human primary nasal epithelial cells [Internet]. 2021 [cited 2022 Jan 9]. Available from: <https://www.gov.uk/government/publications/imperial-college-london-omicron-vs-delta-replication-19-december>.
- 28) Viana R, Moyo S, Amoako D, Tegally H, Scheepers C, Althaus C, et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. *medRxiv* [Internet]. 2021 [cited 2021 Dec 21]; Available from: <https://ceri.africa/publication/?token=369>.
- 29) Yang W, Shaman J. SARS-CoV-2 transmission dynamics in South Africa and epidemiological characteristics of the Omicron variant [Internet]. Columbia University; [cited 2021 Dec 21]. Available from: http://www.columbia.edu/~jls106/yang_shaman_omicron_sa.pdf.
- 30) Take all measures to prevent further spread of Omicron – WHO18 December 2021 News release SEAROSEAR/PR/1777New Delhi, 18 December 2021.
- 31) The Hindu, First death with Omicron variant in United Kingdom(2021). Available online: <https://www.thehindu.com/news/international/first-death-with-omicron-variant-in-united-kingdom/article37950265>. Ece (accessed on December 2021).
- 32) Indian Express, Covid-19 Numbers Explained: Omicron cases in US less than 1,500 but infections could be over six lakh (2021).<https://indianexpress.com/article/explained/covid-19-numbers-explained-omicron-us-cases-7683032/> (Accessed on December 2021).
- 33) Indian Express, Corona virus News Highlights: Delhi reports nearly 500 new Covid cases, test positivity rate jumps to 0.89% (2021).<https://indianexpress.com/article/india/coronavirus-news-live-omicron-modi-covid-vaccine-booster-7690706/> (accessed on December 2021).
- 34) E Times News, Corona virus: Are children at risk of developing severe Omicron infection? Available online <https://timesofindia.com/life-style/health-fitness/health-news/corona-virus-are-children-at-risk-of-developing-severe-omicron-infection/photostory/88141222.cms> (accessed on December 2021).